Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

Inclusion Criteria: * Age 50 or older * Subject is able to sign informed consent * Ability to complete 6 month trial * Present with advanced AMD and persistently leaking CNV * Adequate hematologic, renal and liver function * Negative pregnancy test * Subject is able to safely undertake all protocol directed instructions * Visual acuity of 20/200 (logMAR 1.0)(6/60) or worse Exclusion Criteria: * Concomitant eye disease in eye to be treated * Prior ocular radionuclide treatments * Known allergic or hypersensitivity reactions to light and/or fluorescein and iodine or shellfish * History of investigational drug or therapy including biologics within 30 days prior to the study drug dosing * Women who are pregnant or lactating, or women of childbearing years not taking adequate contraception precautions * History of porphyria, systemic lupus erythematosus, or xeroderma pigmentosum * History of clinically significant cardiovascular abnormalities, including myocardial infarction in the past 6 months, uncontrolled arrhythmias, uncontrolled congestive heart failure * Concomitant use of other drugs known to produce skin photosensitivity, e.g. tetracycline, sulfonamides, phenothiazines, sulfonylureas, thiazide diuretics and griseofulvin, St. John's Wort * Subjects with high or pathological myopia with an axial length \> 26mm or a refractive error of \>/= -8.00D * Subjects with glaucoma and vision loss in either eye * Subject with a history of other choroidal leakage, e.g. histoplasmosis * Subjects with significant media opacity * Subjects diagnosed with diabetic retinopathy * Subjects who have had eye surgery within the past 3 months * Subjects who have received PDT treatment for AMD in the treatment eye * Any disease or condition that the sponsor or the investigator believes will impact the subject's ability to adhere to the study schedule * Subjects participating in any concurrent trial